The COVID-19 pandemic has prompted pharmaceutical companies across the world to develop contingency plans to tackle potential disruptions.
GlobalData has conducted a survey to determine if companies across North America, Asia Pacific (APAC), Europe and Rest of World (ROW) have developed scenarios to respond to coronavirus-related disruptions.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
An analysis of the survey responses has revealed that planning for COVID-19 related disruptions was highest in North America in Q3 at 91%, compared to 78% in Q1, as companies began to develop contingency plans.
In Europe, the percentage of companies that had developed planning scenarios increased from 63% in Q1 to 71% in Q3.
The survey, further, found that 56% of the respondents from APAC had planned for disruptions related to COVID-19 in Q1, which increased to 67% in Q3. For companies in ROW, however, the figure dropped from 70% in Q1 to 60% in Q3.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe analysis is based on responses received from the Pharmaceutical Trade and Supply Chain Survey conducted between 07 July and 30 July 2020.
